Evaluation of intravenous regional block with low- dose infliximab for patients with Complex Regional Pain Syndrome
- Conditions
- Patients with Complex Regional Pain Syndrome
- Registration Number
- JPRN-UMIN000016048
- Lead Sponsor
- Fukuoka University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 5
Not provided
1. The following laboratory data Hb<8.5g/microliter WBC<3.5*1000cells/microliter Neutrophil<1.0*1000cells/microliter PLT<5*10000cells/microliter ALT or AST>1.5*ULN Total Bilirubin>ULN Cr>=2.0mg/dL (NT-pro BNP>=125pg/ml) 2. Patients have severe, progressive or uncontrolled kidney disease, liver disease, skin disease, blood disease, digestive disease, endocrine disease, lung disease, cardiac disease, or neurological disease. 3. Patients had been hospitalized within 3 months for cardiac event(myocardial infarction or unstable angina), stroke or TIA. 4. Patients had severe infection within 2 months. 5. Patients have congestive heart failure in NYHA class 2 to 4. 6. Patients had relapse or progressive infectious disease including chronic renal infection, chronic chest infectious disease or urinary tract infection. Patients have past history of open drainage wound or ulcer. 7. Abnormal finding of interstitial pneumonia, tuberculosis, or other diseases on chest X-ray within 3 months 8. Past history of demyelinating disease including multiple sclerosis or optic neuritis 9. Patients have past history of gastrointestinal perforation or have active diverticulitis. 10. Patients had non-tuberculous mycobacterial infection or opportunistic infection within 6 months. 11. Hepatitis C positive 12. Hepatitis B positive 13. Patients have malignant neoplasm or had it within 5 years 14. Pregnant or lactating mother 15. Patients have steroid medication. 16. Investigator considers that the enrollment in this study is not benefit for the patient or intravenous regional sympathetic nerve blocking is impossible for the patient.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain intensity
- Secondary Outcome Measures
Name Time Method 1 Edema 2 Serum concentration of TNF-alpha 3 Allodynia 4 Skin color change 5 Skin temperature change